Skip to content

EXOZ EXOZ Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Ginkgo Bioworks logo
Ginkgo BioworksDNA
NAG
Niagen Bioscience, Inc. Common StockNAGE
Nature's Sunshine Products logo
Nature's Sunshine ProductsNATR
Opko Health logo
Opko HealthOPK
Upexi logo
UpexiUPXI
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST

Other financials

Income statement

See full
Revenue$17.5K
Operating income-$2.4M-22.4%
Net income-$2.4M-27.7%
EPS (diluted)-$0.28-27.3%

Balance sheet

See full
Cash & equivalents$1.4M-83.0%
Total debt$1.2M-8.8%
Total equity$1.5M-82.8%
Total assets$4.0M-65.1%

Cash flow

See full
Operating cash flow-$1.5M-34.5%
CapEx$57.6K+85.5%
Free cash flow-$1.6M-35.8%

Valuation

See full
Market cap$76.8M-5.6%
Enterprise value$76.57M+1.0%
P/S1,096.1×

Profitability

See full
Operating margin-14,489.6%
Net margin-2,909.1%
FCF margin-10,117.8%

Returns & leverage

See full
Return on equity-185.8%
Debt / equity0.8×+0.6×
Current ratio1.3×-5.2×

Where this comes from

Reported directly by EXOZ in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsOther.

The official record: EXOZ’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about EXOZ's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EXOZ's deferred tax assets and other non-current assets?
EXOZ (EXOZ) reported deferred tax assets and other non-current assets of $67.37K in Q4 2025.
What is the long-term trend for EXOZ's deferred tax assets and other non-current assets?
Over 2 years (2023 to 2025), EXOZ's deferred tax assets and other non-current assets has grown at a 0.0% compound annual growth rate (CAGR), from $67.37K to $67.37K.